|
The potential of using monoclonal antibodies (mAbs) that specifically target tumor antigens for in vivo diagnosis therapeutics has been realised. However, the use of murine antibodies for such purposes is limited by their immunogenicity that provokes immune response known as human anti-mouse antibody (HAMA) reaction.
Therefore, humanisation of murine antibody is paramount for clinical applications. Our Protein Science team offers fully integrated technology for developing and creating antibodies and for transforming non-human antibodies into HUMANISED form that can be safely administered into patients.
Monoclonal Antibody Production- Immunisation of mice or rats
- Fusion / screening / cloning of cells
- Development of hybridoma cell lines
- Assessment of specificity and avidity
- Non-GMP cell banking for hybridoma
Construction of Chimeric Antibody- Extraction of mRNA from hybridoma
- Synthesis of cDNA
- Cloning and verification of Vk (light chain) and Vh (heavy chain) sequences.
- Ligation of Vk and Vh into expression vectors
- Transfection of expression vectors carrying Vk and Vh into NSO and CHO cell lines.
- Selection of high-producing clones using ClonePixTM FL system
- Culture and maintenance of antibody producing cell lines
- Immunogenicity tests on non-human primates
Construction of Humanised Antibody- Extraction of mRNA from hybridoma
- Synthesis of cDNA
- Cloning and verification of Vk (light chain) and Vh (heavy chain) sequences.
- Ligation of Vk and Vh into expression vectors
- Chimerisation and recognition of amphipatic sites
- Introduction of mutations to complement human sequence.
- Transfection of expression vectors carrying Vk and Vh into NSO and CHO cell lines.
- Selection of high-producing clones using ClonePixTM FL system.
- Culture and maintenance of antibody producing cell lines.
- Immunogenicity tests on non-human primates
|
